Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
Clinical trial NCT04798001 · UNKNOWN
Trial details
- NCT number
- NCT04798001
- Sponsor
- Meissa Vaccines, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-12
- Primary completion
- 2022-10-31
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.